Apex Biotechnology Corp (TW:1733) — Market Cap & Net Worth
Market Cap & Net Worth: Apex Biotechnology Corp (1733)
Apex Biotechnology Corp (TW:1733) has a market capitalization of $94.15 Million (NT$2.99 Billion) as of September 17, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #19485 globally and #1098 in its home market, demonstrating a -5.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apex Biotechnology Corp's stock price NT$29.90 by its total outstanding shares 99950192 (99.95 Million). Also see how large is Apex Biotechnology Corp's balance sheet for a full breakdown of the balance sheet.
Apex Biotechnology Corp Market Cap History: 2015 to 2026
Apex Biotechnology Corp's market capitalization history from 2015 to 2026. Data shows change from $116.87 Million to $94.15 Million (-0.92% CAGR). Also see 1733 operating cash flow for how efficiently the company converts equity into cash flow.
Apex Biotechnology Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apex Biotechnology Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 1733 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.05x
Apex Biotechnology Corp's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.74x
Apex Biotechnology Corp's market cap is 0.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $116.87 Million | $1.85 Billion | $261.85 Million | 0.06x | 0.45x |
| 2016 | $107.26 Million | $1.76 Billion | $3.18 Million | 0.06x | 33.72x |
| 2017 | $83.63 Million | $1.80 Billion | $85.55 Million | 0.05x | 0.98x |
| 2018 | $79.97 Million | $2.04 Billion | $95.12 Million | 0.04x | 0.84x |
| 2019 | $78.46 Million | $2.20 Billion | $113.86 Million | 0.04x | 0.69x |
| 2020 | $68.34 Million | $2.01 Billion | $94.80 Million | 0.03x | 0.72x |
| 2021 | $77.92 Million | $2.13 Billion | $202.22 Million | 0.04x | 0.39x |
| 2022 | $80.46 Million | $2.24 Billion | $181.78 Million | 0.04x | 0.44x |
| 2023 | $126.90 Million | $1.68 Billion | $115.78 Million | 0.08x | 1.10x |
| 2024 | $94.78 Million | $1.85 Billion | $128.00 Million | 0.05x | 0.74x |
Competitor Companies of 1733 by Market Capitalization
Companies near Apex Biotechnology Corp in the global market cap rankings as of September 17, 2026. Review Apex Biotechnology Corp tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Apex Biotechnology Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Apex Biotechnology Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Apex Biotechnology Corp's market cap moved from $116.87 Million to $ 94.15 Million, with a yearly change of -0.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$94.15 Million | -1.81% |
| 2025 | NT$95.89 Million | +1.16% |
| 2024 | NT$94.78 Million | -25.31% |
| 2023 | NT$126.90 Million | +57.73% |
| 2022 | NT$80.46 Million | +3.25% |
| 2021 | NT$77.92 Million | +14.02% |
| 2020 | NT$68.34 Million | -12.90% |
| 2019 | NT$78.46 Million | -1.88% |
| 2018 | NT$79.97 Million | -4.38% |
| 2017 | NT$83.63 Million | -22.03% |
| 2016 | NT$107.26 Million | -8.23% |
| 2015 | NT$116.87 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Apex Biotechnology Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $94.15 Million USD |
| MoneyControl | $94.15 Million USD |
| MarketWatch | $94.15 Million USD |
| marketcap.company | $94.15 Million USD |
| Reuters | $94.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more